BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on BRILINTA, talking to your doctor, and. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start . 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed.
|Country:||United Arab Emirates|
|Published (Last):||28 July 2013|
|PDF File Size:||15.59 Mb|
|ePub File Size:||6.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
BRILINTA® (ticagrelor) tablets | For Health Care Professionals
Cabozantinib is a P-gp inhibitor and has the potential to increase plasma concentrations of P-gp substrates; however, the clinical relevance of this finding is unknown. The nasogastric tube must be flushed with water after administration of the mixture. Pacckage Avoid coadministration of ticagrelor with voriconazole due to increased plasma concentrations of ticagrelor resulting in an increased risk of dyspnea, bleeding, and other treatment-related adverse reactions.
AV block, bradycardia, sick sinus syndrome, syncope. Moderate Due to the risk for terbinafine related adverse effects, caution is advised when coadministering ticagrelor. A dose reduction, interruption of therapy, or discontinuation of nintedanib therapy may be necessary.
Moderate Coadministration of ticagrelor and mefloquine may result in increased exposure to ticagrelor which may increase the bleeding risk. Monitor patients during anagrelide therapy for cardiovascular effects and evaluate as necessary.
Ticagrelor is contraindicated in any patient with active pathological bleeding including pwckage ulcer GI bleeding or intracranial bleeding. Moderate Monitor for evidence of bleeding if coadministration of dasatinib and ticagrelor is necessary.
Moderate Coadministration of ticagrelor and lapatinib may result in increased exposure to ticagrelor which may increase the bleeding risk. Minor Coadministration of ticagrelor and dronedarone may result in increased exposure to ticagrelor which may pac,age the bleeding risk.
Concomitant platelet inhibitors may increase the risk of hemorrhage. Moderate Monitor digoxin concentrations when used concomitantly with ticagrelor.
In addition, dose-related increases in mean QTc and heart rate were observed in healthy subjects. Moderate Platelet aggregation may be impaired by vortioxetine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e. Moderate Plasma concentrations of ticagrelor, a P-glycoprotein P-gp substrate, may be increased when administered concurrently with ;ackage, a P-gp inhibitor.
Share With a Friend
Moderate Use caution if coadministration of telotristat ethyl and ticagrelor is necessary, as the systemic exposure of ticagrelor may be decreased resulting in reduced efficacy; exposure to telotristat ethyl may also be increased. In addition, the birlinta to isavuconazonium may be increased resulting in potential adverse effects. Major Concomitant use of lomitapide and packaeg may significantly increase the serum concentration of lomitapide.
Receipt of injectable collagenase may cause an ecchymosis or bleeding at the injection site. You may report side brilknta related to AstraZeneca products by clicking here.
Avoid maintenance doses of aspirin above mg daily. Moderate Because ticagrelor inhibits platelet aggregation, a potential additive pharmacodynamic effect for bleeding exists if ticagrelor is given in combination with other agents that affect hemostasis such as warfarin, heparin, or low-molecular weight heparins LMWHs.
When administered as crushed tablets mixed in water either orally or via nasogastric tube, the mixture is bioequivalent to whole tablets with a median tmax of 1 hour for ticagrelor and 2 hours for the active metabolite.
Both drugs are P-glycoprotein P-gp bdilinta and inhibitors. Major Avoid coadministration of ticagrelor with ribociclib due to increased plasma concentrations of ticagrelor resulting in an increased risk of dyspnea, bleeding, and other treatment-related adverse reactions. Ticagrelor is a substrate and inhibitor of the hepatic isoenzyme CYP3A4 and substrate of the drug transporter P-glycoprotein P-gp ; isavuconazole, the active moiety of isavuconazonium, is a sensitive substrate and moderate inhibitor of CYP3A4 and an inhibitor of P-gp.
Ticagrelor is a P-glycoprotein P-gp substrate and erythromycin is a P-gp inhibitor.
Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein P-gp. Minor Coadministration inserh ticagrelor and vemurafenib may result in increased exposure to ticagrelor which may increase the bleeding risk. Consider delaying the onset of defibrotide treatment until the effects of the antithrombotic agent have abated. Major Avoid coadministration of ticagrelor with darunavir due to insetr plasma concentrations of ticagrelor resulting in an increased risk of dyspnea, bleeding, and other treatment-related adverse reactions.
Because many drugs are excreted in human milk; the manufacturer recommends that ticagrelor or breast-feeding be discontinued because of the potential for serious adverse reactions in nursing infants. Your email has been sent. Minor Coadministration of ticagrelor and simeprevir may result in increased exposure to ticagrelor which may increase the bleeding risk. Minor Monitor for an increase in ticagrelor-related adverse reactions if coadministration with cabozantinib is necessary.
Ticagrelor is a CYP3A4 substrate. Consider discontinuation of ADP receptor antagonists in a patient taking inotersen with a platelet count of less than 50, per microliter. In addition, ticagrelor is a weak inhibitor of the hepatic enzyme CYP3A4. An additive risk of bleeding may be seen in patients receiving other platelet inhibitors in combination with pentosan.
If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA. Ticagrelor is an inhibitor of the drug transporter P-glycoprotein P-gp.